{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=55&state=Wisconsin", "query": { "state": "Wisconsin", "city": "Milwaukee", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 5350, "total_pages": 535, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=56&state=Wisconsin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=54&state=Wisconsin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T16:03:00.101Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02571907", "title": "PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortoiliac Aneurysms", "Iliac Aneurysms" ], "interventions": [ { "name": "Zenith® Branch Endovascular Graft-Iliac Bifurcation,", "type": "DEVICE" }, { "name": "Atrium iCAST™", "type": "DEVICE" }, { "name": "Zenith® Flex AAA Endovascular Graft", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cook Research Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2014-04-01", "completion_date": "2020-11-04", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Palo Alto, California • Stanford, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02571907" }, { "nct_id": "NCT04987307", "title": "Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Efavaleukin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 221, "start_date": "2022-01-31", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 63, "location_summary": "Dothan, Alabama • Homewood, Alabama • Mesa, Arizona + 57 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987307" }, { "nct_id": "NCT03515044", "title": "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overt Hepatic Encephalopathy" ], "interventions": [ { "name": "40 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "40 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2018-09-13", "completion_date": "2020-03-12", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 34, "location_summary": "Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Corona del Mar", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bristol", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515044" }, { "nct_id": "NCT02025751", "title": "Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Gastroparesis" ], "interventions": [ { "name": "Metoclopramide Nasal Spray", "type": "DRUG" }, { "name": "Placebo Nasal Spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Evoke Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 53, "start_date": "2014-04", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02025751" }, { "nct_id": "NCT00554229", "title": "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "ZD4054", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 896, "start_date": "2007-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 19, "location_summary": "Tucson, Arizona • Greenbrae, California • Los Angeles, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00554229" }, { "nct_id": "NCT01130272", "title": "Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Eluxadoline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Furiex Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 807, "start_date": "2010-04-28", "completion_date": "2011-07-14", "has_results": true, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 288, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130272" }, { "nct_id": "NCT05301101", "title": "High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Re-irradiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-06-13", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05301101" }, { "nct_id": "NCT00210665", "title": "A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-10-10", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 31, "location_summary": "Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00210665" }, { "nct_id": "NCT00761267", "title": "Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia" ], "interventions": [ { "name": "Anidulafungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 70, "start_date": "2009-02", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2019-04-04", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 24, "location_summary": "Long Beach, California • Los Angeles, California • Oakland, California + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00761267" }, { "nct_id": "NCT03263936", "title": "Epigenetic Reprogramming in Relapse/Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 37, "start_date": "2017-07-11", "completion_date": "2022-02-10", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-29T16:03:00.101Z", "location_count": 28, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03263936" } ] }